Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -7.59% and 11.20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is ...

Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) is expected to announce its earnings results after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of ...

Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics, Inc. (NASDAQ:SAGE) recently received an unsolicited bid proposal from Biogen Inc. (BIIB) to be purchased at around $7.22 per share. This represents a 30% premium to the price of ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known ...